The Cochrane Skin Group: a vanguard for developing and promoting evidence-based dermatology by Reddi, Anand et al.
Journal of Evidence-Based Medicine ISSN 1756-5391
ORIGINAL ARTICLE
The Cochrane Skin Group: a vanguard for developing and
promoting evidence-based dermatology
Anand Reddi1, Laura Prescott2, Elizabeth Doney2, Finola Delamere2, Ramya Kollipara1,
Robert P Dellavalle1,3,4 and Hywel C Williams2
1 Department of Dermatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA
2 Centre of Evidence-Based Dermatology, University of Nottingham King’s Meadow Campus, Nottingham, UK
3 Department of Dermatology, Denver Veterans Administration Hospital, Denver, CO, USA
4 Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA
Keywords
Cochrane; skin; evidence; epidemiology;
dermatology.
Correspondence
Hywel C Williams, Dermato-epidemiology,
Centre of Evidence Based Dermatology,
University of Nottingham, Nottingham
University Hospitals NHS Trust; Queen’s
Medical Centre, Nottingham NG7 2UH, UK.,
Tel: 44-0-115-8231048;
Fax: 44-0-115-8231046;
Email: hywel.williams@nottingham.ac.uk
Contribution of authors
F Delamere is the Managing Editor of the
Cochrane Skin Group, E Doney is the Trials
Search Coordinator, L Prescott is the Editorial
Assistant, and H Williams is the Coordinating
Editor. RP Dellavalle is a CSG Editor. A Reddi
and R Kollipara are member of the CSG.
Received 20 September 2013; accepted for
publication 26 October 2013.
doi: 10.1111/jebm.12068
Abstract
Aim: The Cochrane Skin Group (CSG) is part of the international Cochrane Collab-
oration (http://www.cochrane.org/). The CSG prepares, maintains and disseminates
high quality evidence-based summaries on the prevention, diagnosis and treatment
of skin diseases. We present a synopsis of the history, scope and priorities of the
CSG. In addition, we report outcomes of CSG reviews and critically assess clinical
value.
Methods: Descriptive analysis of systematic reviews published by the CSG since
its inception including output, impact factor, associated methodological studies,
and influence in clinical guidelines, promoting patient and public engagement and
in triggering new primary research.
Results: The CSG started in 1997, and has published 61 reviews, 34 protocols and
31 registered titles by August 2013. The CSG scope includes 1000 skin diseases;
80% of reviews cover the top ten diagnoses and 40% of reviews provide clear
guidance for clinical practice. CSG reviews had an impact factor of 6.1 in 2011
which places it alongside top dermatology journals. CSG reviews are typically broad
in focus and have been shown to be of better quality than non-Cochrane reviews.
They are highly cited in clinical guidelines. Several reviews have identified evidence
gaps that have led to better primary research.
Conclusions: The CSG has emerged as a vanguard of evidence-based dermatology
by growing a community interested in applying best external evidence to the care of
skin patients and by identifying topics for research. CSG reviews are high impact,
clinically relevant and have tangibly influenced international dermatology clinical
practice guidelines and new research.
Introduction
To celebrate the 20th anniversary of The Cochrane Collabo-
ration, it would be remiss not to start by honoring the Col-
laboration’s namesake: Professor Archie Cochrane. In 1979,
Cochrane declared: “It is surely a great criticism of our pro-
fession that we have not organized a critical summary, by
specialty or subspecialty, adapted periodically, of all rele-
vant randomized control trials” (1). Professor Cochrane’s
bold declaration provided a new raison d’eˆtre for modern
evidence-based medicine to integrate the best external evi-
dence in the care of individual patients according to specific
areas of health such as skin diseases. Today, Cochrane sys-
tematic reviews have become a gold standard in informing
evidence-based medicine. Cochrane Reviews have diversi-
fied beyond simple reviews of therapeutic interventions to
also include reviews of the accuracy of diagnostic tests and
other products such as overviews of families of related sys-
tematic reviews, accompanied by a body of cutting edge
methodology needed to support these advances. Cochrane’s
legacy has had a profound impact on all medical specialties,
including dermatology.
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The Cochrane Skin Group: Origins,
Scope, and Priorities
In 1992, Iain Chalmers published an editorial in The British
Medical Journal advocating the need to get to grips with
Archie’s Cochrane agenda (1). One of the authors of the
present article (HCW), a trainee in epidemiology at the time
inspired by Chalmers’editorial wrote to him, supporting his
call for summarizing systematically what was already known
in dermatology. Chalmers’ response was immediate, wel-
coming, and encouraging. As a result, a collection of people
interested in evidence-based dermatology and systematic re-
views gathered over the next four years until a critical mass
formed, resulting in an exploratory meeting in 1996 with
view to forming a Cochrane Skin Group (CSG). Preparation
and engagement with a range of stakeholders including pa-
tients at that exploratory meeting was key, and the minutes
are still posted on The Cochrane Collaboration website as an
exemplar of how to get a group started. Iain Chalmers him-
self contributed to the meeting, along with his brother Robert
Chalmers, a dermatologist who has been an active member
of the CSG ever since.
On the 12 September 1997, the CSG officially registered
with The Cochrane Collaboration. The CSG aims to dissem-
inate evidence-based guidelines to prevent, diagnose, and
treat dermatological disease. Over the last 16 years, the CSG
has emerged as a vanguard of evidence-based dermatology
and dermato-epidemiology on an international scale (2–4).
The CSG will review any aspect of skin disease man-
agement of value to professionals or to lay people with an
interest in skin disease. The scope includes reviews ranging
from life-threatening melanoma skin cancer, through around
1000 skin conditions, such as eczema, acne, and vitiligo, to
areas that are considered by some to be simply cosmetic in
nature, such as skin damage due to the sun.
Sometimes, other Cochrane groups also produce reviews
relevant to dermatology due to the broad nature of our field.
For example, the Cochrane Wounds Group has published
reviews covering leg ulcers and treatments for scars such
as keloids. A robust system is in place within The Cochrane
Collaboration to ensure that all newly proposed titles for pos-
sible reviews are circulated to all groups, in order to initiate
constructive dialogue between groups on how to avoid unin-
tentional overlap and how a review of a multisystem disorder,
such as systemic lupus, can be best supported.
In identifying and prioritizing topics for new reviews, the
CSG considers the following: (i) the impact of the condition
on people’s lives (which may be psychological as well as
physical); (ii) the knowledge gap in treating this condition;
(iii) whether there any other good systematic reviews already
on the subject; (iv) what a Cochrane Review would add to
what is already known; (v) an assessment of the pace of
the field and quality of the evidence on the subject; and
(vi) whether the topic is of current debate or public health
importance.
The CSG’s editorial process is rigorous and has previously
been discussed in depth by Williams et al and Leonard, De-
lamere, and Murrell (2, 5).
Outcomes of the CSG
As of August 2013, the CSG has 61 reviews, 34 protocols,
and 31 registered titles. We performed a citation analysis
of all CSG papers published in The Cochrane Library us-
ing Google Scholar. Of the 61 reviews published to date
(including updates), there are more than 2800 citations. Ta-
ble 1 presents the top 12 cited CSG papers and their key
findings (6–17). Since the inception of the CSG, nearly 800
authors have contributed to our reviews.
Impact
How do we measure the impact of the CSG?
One traditional metric is the Thomson Institute for Scientific
Information’s journal impact factor. The impact factor for the
CSG has been steadily increasing in recent years. In 2010,
it was 6.0 and in 2011, it was 6.1. To provide some context,
the top journal in the field of dermatology, The Journal of
Investigative Dermatology, had an impact factor of 6.3 in
2011. So, it appears, from an editorial standpoint, that the
CSG is publishing papers that are highly cited in the der-
matology field vis-a`-vis other dermatology journals. Yet, the
impact factor metric alone maybe an imprecise measure of
actual clinical ‘impact’ on dermatology practice, as it does
not measure quality or relevancy of articles (18, 19).
Is the CSG producing high-quality reviews?
A study by Collier et al in 2006 concluded that CSG reviews
are of higher quality than non-Cochrane dermatology system-
atic reviews (20). The authors determined the methodologi-
cal quality of Cochrane and non-Cochrane reviews, using the
10-item Oxman and Guyatt scale to assess quality (20). The
study revealed that Cochrane Reviews were more likely than
non-Cochrane reviews to include a comprehensive search
strategy, minimize selection bias, and appropriately assess
the validity of all included trials (20). Additionally, Cochrane
Reviews more frequently included quality of life and adverse
outcomes data compared to non-Cochrane reviews (20).
Since the central Cochrane Editorial Unit introduced the
MECIR (Methodological Expectations of Cochrane Inter-
vention Reviews) standards for conducting reviews in 2011,
and for reporting reviews in late 2012, the CSG has been keen
to encourage their use by authors. All members are aware of
the new standards, and links to the expectations are in the
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standard informative material that the CSG sends to all new
authors.
Are CSG reviews relevant to clinical
practice?
A common criticism of Cochrane Reviews is that they are
long and complicated and commonly end up with a bottom
line of ‘insufficient evidence’, which even if strictly true,
most clinicians and patients find unhelpful. In 2004, Parker
and colleagues sought to address the question “What’s the
point of databases of reviews in dermatology if all they com-
pile is insufficient evidence” (21)? By assessing the number
of reviews relevant to dermatology on The Cochrane Library
at the time, and whether those reviews reported sufficient
evidence to guide clinical decision-making (21). They found
that 80% of reviews relevant to dermatology covered the top
10 diagnoses and that 40% of the reviews provided sufficient
evidence to guide clinical practice (21).
Consistent with Parker et al, a study published in 2013 by
Davila-Seijo, Batalla, and Garcia-Doval found that ‘most of
the systematic reviews published by the CSG provide useful
information to improve clinical practice’ (22). The authors
performed a bibliometric analysis of all systematic reviews
published by the CSG through August 2012. Their analysis
graded 55 CSG reviews into three categories: ‘Not useful
in clinical practice: insufficient evidence to support or reject
the use of an intervention’, ‘Useful: insufficient evidence to
support or reject the use of an intervention, but sufficient
evidence to support recommendations or suggestions’, and
‘Very useful: strong evidence to support or reject the use
of an intervention’ (22). They classified 25.5% (14/55) as
not useful in clinical practice, 45.5% (25/55) as useful, and
29.1% (16/55) as very useful (22). Even when studies are
not considered useful in clinical practice, when evidence is
lacking, ‘Cochrane reviews identify gaps in knowledge and
help frame the future research agendas’ (5). Nevertheless, it
appears that the majority of systematic reviews published by
the CSG provide useful information in guiding dermatology
clinical practice (20, 22).
Is the CSG changing dermatology clinical
practice and guidelines?
Table 2 presents five notable examples of CSG reviews that
have influenced dermatology clinical practice and guide-
lines (14, 23–26). The CSG is having a tangible effect on
international dermatological health policy including guide-
line contributions to the United Kingdom’s National Institute
for Health and Clinical Excellence and the National Health
Service, the Scottish Intercollegiate Guidelines Network, the
British Association for Dermatology and the American As-
sociation of Dermatology.
Additionally, the juxtaposition of the CSG alongside the
UK Dermatology Clinical Trials Network (UKDCTN) at the
Centre of Evidence Based Dermatology in Nottingham, UK,
has led to new studies initiated by the UKDCTN on the
basis of research gaps identified from CSG research. As an
example, the current international clinical trial of tetracycline
versus prednisolone for bullous pemphigoid arose from a
Cochrane Review on this topic (27).
Dissemination of CSG reviews to the
dermatology community and public: a need
for partnerships
The CSG is keen to encourage dissemination of informa-
tion about our reviews to ensure that it reaches a broad
global audience of dermatologists, scientists, policy mak-
ers, and patients. Recently, the CSG initiated co-publishing
agreements for publishing abridged versions of our reviews
with two of the most widely read clinical dermatology jour-
nals: The Journal of the American Academy of Dermatology
and The British Journal of Dermatology. Additionally, the
CSG manages a website to disseminate research activities
(www.skin.cochrane.org). We are also exploring increasing
our social media presence as this is an emerging area to
disseminate public health information (28). Opportunities
may exist to increase our presence on Facebook and Twit-
ter, as well as to provide author podcasts of recent CSG
reviews (29).
The CSG is very interested in promoting patient advocacy
and involves patients with skin diseases and their families
(consumers). The majority of dermatological trials have fo-
cused on questions relevant to academic research and phar-
maceutical companies, and these trials miss an important
opportunity to seek patient’s perspectives, especially with
regard to nonpharmacological interventions such as educa-
tion or specialized clothing. Patient perspectives on choice
of appropriate outcomes, for example, are important, and
increase awareness among researchers to improve interven-
tions especially in areas such as adherence to medication and
treatment satisfaction. About 100 active consumers are mem-
bers of the CSG and are involved at many levels. Initially, the
National Eczema Society and the Vitiligo Society of the UK
provided the majority of our consumers. But, today, since we
always include a relevant consumer in the peer-review pro-
cess and often as a co-author on CSG reviews, many other
patient advocates have joined the CSG.
The CSG is also active in developing global alliances. Cur-
rently, we have a satellite group in France and are initiating
another in the United States. We are also interested in continu-
ing to expand participation by individuals in low- and middle-
income countries and to increase reviews on evidence-based
dermatology guidelines relevant to resource-limited settings.
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Table 2 Notable examples of Cochrane Skin Reviews that have influenced clinical practice and health policy
CSG Title/reference Influence on clinical practice and health policy
Interventions for bullous
pemphigoid (14)
British Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012. Br J
Dermatol 2012; 167(6): 1200–14.
Topical treatments for
chronic plaque psoriasis
(23)
National Clinical Guideline Centre; National Institute for Health and Clinical Excellence. Psoriasis:
assessment and management of psoriasis. London: National Clinical Guideline Centre, Royal College of
Physicians; 2012. (NICE CG153). [Issued October 2012]. Available from URL: http://guidance.nice.org.uk
Interventions for
non-metastatic squamous
cell carcinoma of the skin
(24)
NHS Evidence update of the NICE skin cancer guidelines: Williams HC, Bath-Hextall F, Dewar D, Kelly C,
Lansbury L, Lear J, Newton-BishopJ, Schofield J. Improving outcomes for people with skin tumours
including melanoma: Evidence Update October 2011. National Institute for Health and Clinical Excellence,
October 2011. Available from URL: http://www.evidence.nhs.uk/topic/skin-cancer
Anti-streptococcal
interventions for guttate
and chronic plaque
psoriasis (25)
Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of psoriasis and psoriatic
arthritis in adults. Edinburgh: SIGN; 2010. (SIGN publication no. 121). [cited 12 Oct 2010]. Available from
URL: http://www.sign.ac.uk
Safety of topical
corticosteroids in
pregnancy (26)
American Association of Dermatology guideline on treatments for pregnant women with psoriasis: Bae YS,
Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M. Review of treatment options for psoriasis
in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad
Dermatol 2012; 67(3): 459–77.
Challenges, Opportunities, and
Future Plans
Editorial process
Our process for registering a review title requires a new
review team to include an experienced Cochrane author who
has previously led a Cochrane Review, a methodologist or
statistician, a content expert, a consumer, and an author with
a good command of written English. This requirement has
been in place for some years but has not been sufficient
to ensure that all reviews progress to an acceptable standard
within the agreed timelines. More recently, the CSG Editorial
Base has introduced a categorization system where authors
of submitted protocols (and subsequent reviews) are given an
indication of whether their work is immediately acceptable
to be sent to the referees or whether they need to make minor
or major changes before it can be go to this step. If these
requirements cannot be met at the protocol stage, this may
be an indication the review team is not able to produce a
quality review.
We would like to see the CSG become more selective with
its content. To do this, it will be necessary to occasionally
say ‘no’ to reviews that are not good enough—just as other
journals turn down submissions.
Discourage reviews of limited focus and
interest
The CSG has always steered authors away from very narrow
topics of limited usefulness, and instead encouraged broader
review titles, such as ‘Interventions for . . . ’ However, sub-
sequent updates of these broad reviews can become too large
and unmanageable for review authors, referees, the Editorial
Base, and readers. Updated reviews such as ‘Interventions
for vitiligo’ grew from 19 included trials in 2007 to 57 trials
in the 2010 update. The recently updated ‘topical treatments
for chronic plaque psoriasis’ included 190 studies in the 2013
update. A challenge for the future is how to continue to pro-
duce reviews that assess broad topics in a manageable way.
Identifying priority topics
We wish to evolve the prioritization process to encourage
reviews on areas that have significant human implications
and financial costs to healthcare providers, as well as orphan
diseases and those that represent current dilemmas. We want
potential review teams to ‘bid’ for these priority titles, ex-
plaining why their team is best suited to complete the review
to a high standard in a timely way.
Promote reviews of dermatology therapies
of relevance to the developing world
Our group is also conscious of the need to cover skin condi-
tions that commonly affect people in low- and middle-income
countries as exemplified by our two reviews on cutaneous and
mucocutaneous leishmaniasis (30, 31). One of which ‘inter-
ventions for American cutaneous and mucocutaneous leish-
maniasis’ won the Pan American Health Organization prize
in 2010, because of its relevance to the Health Agenda for
the Americas as it addressed a neglected tropical disease.
We also wish to strengthen our global health collaborations
with bodies such as the World Health Organization and the
Institute for Health Metrics and Evaluation at the University
of Washington (that produces the Global Burden of Disease
Survey).
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Conclusion
The CSG has been a key driver for promoting and produc-
ing evidence-based dermatology summaries over the last 13
years. CSG reviews are high impact, clinically relevant, and
have tangibly influenced international dermatology clinical
practice guidelines. Expanding into new areas of research
including those relevant to the developing world, and in-
creasing dissemination of our results via social media will be
important future growth areas for the Group.
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